---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-005787"
form_type: "8-K"
ticker: "CNSP"
cik: "0001729427"
company_name: "CNS Pharmaceuticals, Inc."
filed_at: "2023-08-15T23:59:59+00:00"
generated_at: "2026-06-11T09:30:35.737311+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# CNS Pharma amends bylaws; reduces quorum, eliminates written consent

## Summary
- Reduced stockholder quorum from a majority to one-third of shares outstanding.
- Eliminated action by written consent of stockholders; all actions require a meeting.
- Clarified vote standard: majority of votes cast (excl. abstentions) for most matters; plurality for directors.
- Adds requirement that nominating persons comply with Rule 14a-19 for proxy solicitations.
- Director removal requires two-thirds of voting power; other technical edits and conforming changes.

## SEC filing metadata
- accession: 0001683168-23-005787
- form_type: 8-K
- ticker: CNSP
- cik: 0001729427
- company_name: CNS Pharmaceuticals, Inc.
- filed_at: 2023-08-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1729427/000168316823005787/0001683168-23-005787-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1729427/000168316823005787/cns_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-005787
- JSON: https://secwatch.observer/filing/0001683168-23-005787.json
- Plain text: https://secwatch.observer/filing/0001683168-23-005787.txt

## Key facts
- Governance Changes
  CNS Pharmaceuticals, Inc.: Reduced quorum requirement from majority to one-third of shares outstanding; specified vote standard for stockholder actions; eliminated stockholder action by written consent; added director removal provision requiring two-thirds vote; updated remote meeting, director meeting, and officer provisions (effective 2023-08-11).
  - Change: bylaw amendment
  - Effective: 2023-08-11
  source text: On August 11, 2023, the Board of Directors of CNS Pharmaceuticals, Inc. (the “Company”) adopted the Amended and Restated Bylaws of CNS Pharmaceuticals, Inc. (as amended and restated, the “Bylaws”), effective on such date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1729427/000168316823005787/0001683168-23-005787-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.